###### Key messages

What is the key question?
=========================

-   Can autosetting CPAP treatment effectively treat the neurocognitive dysfunction and sleepiness that is secondary to the sleep-disordered breathing caused by acute cervical spinal cord injury (quadriplegia)?

What is the bottom line?
========================

-   No significant difference was observed in the improvement in attention and information processing; however, sleepiness improved significantly with autosetting CPAP therapy between the treatment and usual care groups.

Why read on?
============

-   This rigorous and challenging study in a unique model of acute sleep-disordered breathing provides insights into the effect of CPAP on neuropsychological outcomes.

Introduction {#s1}
============

Traumatic spinal cord injury is a rare but devastating event with an estimated average global incidence of 23 cases per million[@R1] and prevalence from 236 to 1298 per million.[@R2] The injury age distribution is bimodal: younger, predominantly men, involved in motor vehicle accidents and older people injured during a fall.[@R1] In countries with better acute care, approximately 50% of injuries result in cervical spinal cord injury (quadriplegia/tetraplegia). Life expectancy in quadriplegia is reduced by 20%--30% overall compared with the general population; however, much of this reduction is due to peri-injury mortality, and if people survive the first year after injury, life expectancy is impacted less.[@R3] As such, any prevalent secondary complication will be with a younger person for most of their life and will add to the comorbidities of ageing alongside the quadriplegia per se in an older person. Sleep-disordered breathing (SDB) is one such secondary complication.

SDB, predominantly obstructive sleep apnoea (OSA), can be caused acutely by cervical spinal cord injury[@R4] and is up to five times more prevalent in chronic quadriplegia[@R7] compared with the general population.[@R17] The pathophysiological basis for SDB remain unclear in quadriplegia,[@R19] although both 'spinal specific' issues such as a higher nasal resistance,[@R20] ventilatory control instability,[@R22] altered upper airway reflex responses[@R24] and an increased upper airway lateral wall size,[@R25] coupled with a high rate of 'general population' risks in chronic quadriplegia such as obesity, ageing and a male predominance all contribute.[@R14]

The most effective treatment for SDB is nasal CPAP, but CPAP adherence is challenging in the non-disabled and more so in quadriplegia, with success rates of 20%--50%.[@R13] Left untreated, SDB significantly impairs neurocognitive function,[@R28] increases sleepiness[@R13] and reduces quality of life[@R16] in people with quadriplegia. Untreated, incident SDB is highly likely to adversely impact on learning and skill acquisition during rehabilitation after cervical cord injury. We therefore undertook a randomised controlled trial to address the question of whether CPAP therapy to treat SDB in incident cases of quadriplegia altered outcomes CPAP for Obstructive Sleep Apnoea in Quadriplegia  (COSAQ). The primary hypothesis was that 3 months of autotitrating, CPAP would improve attention and information processing, as measured with the Paced Auditory Serial Addition Task (PASAT) more than usual care.

Methods {#s2}
=======

Study design and governance {#s2a}
---------------------------

The COSAQ study[@R31] was an international, multicentre, randomised, parallel-group trial with blinded outcome assessment. All participants provided written or independently witnessed oral consent if unable to sign.

Participants and outcome measurements {#s2b}
-------------------------------------

All incident cases of traumatic quadriplegia (neurological lesion at first thoracic level or higher and all injury severities) were screened for inclusion across 11 spinal injury units in Australia, Canada, New Zealand and England. Potential participants were excluded if they had successfully used CPAP for SDB prior to injury, had a significant coexistent head injury (Glasgow Coma Scale of \<8 at first assessment), hypercapnia partial pressure of carbon dioxide in arterial blood (PaCO~2~ \>45 mm Hg at randomisation), predicted inpatient stay of less than 3 months, a condition likely to significantly limit CPAP use (eg, major psychoses and facial or base of skull fractures), not proficient in English or unable to provide informed consent.

All consented participants underwent a full, portable sleep study in their hospital beds (Compumedics SomtePSG, Abbottsford, Australia). Those with an apnoea hypopnoea index (AHI) \>10 events per hour[@R32] were trialled on an autotitrating CPAP (S8 and S9, Resmed Autoset, San Diego, California, USA) for up to three nights. All sites received training in and had available a range of patient interfaces (nasal pillows, oronasal and nasal masks, see online [supplementary file](#SP1){ref-type="supplementary-material"}). Participants who tolerated the treatment for at least 4 hours on one of three nights were randomised to receive CPAP immediately (CPAP plus usual care) or wait for 3 months (usual care control). Simple, external, computer-generated, blocked (block size=10) randomisation was performed centrally through the study database. Allocation concealment was maintained by obscuring the randomisation sequence from study site users.
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The same assessor, blinded to allocated group, administered outcome measures at baseline and study completion. The tests included a battery previously demonstrated to reveal neurocognitive limitation in those with quadriplegia and OSA.[@R28] The neurocognitive test battery focused on memory, learning, attention, information processing and executive function (PASAT (primary outcome measure), the Rey Auditory Verbal Learning Test (RAVLT), the Digit Span subtest of the Wechsler Adult Intelligence Scale IV, Symbol Digit Modalities Test and North American Adult Reading Test (NAART)).[@R31] Sleep disorder symptoms and state sleepiness were assessed with the Basic Nordic Sleep Questionnaire (BNSQ)[@R33] and the Karolinska Sleepiness Scale (KSS).[@R34] Health-related quality of life was assessed using the Assessment of Quality of Life Scale[@R35] and mental health and mood using the Hospital Anxiety and Depression Scale and the Profile of Mood States.[@R29] Additional, non-blinded measures of sleepiness (KSS), autonomic dysfunction (diary), CPAP adherence (hours) and troubleshooting of any mask or device issues were made weekly. Spirometry (FVC and FEV~1~) was measured monthly. Participants underwent a repeat sleep study at trial conclusion on CPAP or repeat diagnostic as per randomised group.

All testing was performed at the participants' bedside. Respiratory function, questionnaire and other subjective data were collected at the same time in the mid-afternoon for each subject to control for possible circadian influences. Sleep studies commenced at participants' usual sleep time.

Sample size estimation {#s2c}
----------------------

A sample size of 150 subjects was required to detect a mean difference of 18±33 in the primary outcome (PASAT) at the 0.05 level with 0.8 power, assuming non-adherence to CPAP at 15%. This sample was also adequate to detect a difference of 1 unit in the key secondary outcome of sleepiness (KSS number required=44).[@R31] Further details are available online.

Analyses {#s2d}
--------

The primary analysis was an intention to treat, between randomised group comparison based on random allocation. The *per protocol* analysis was based on CPAP usage where 'adherent' was classified as recorded device use of at least 4 hours on at least five out of seven (70%) nights between randomisation and final neuropsychological assessment.[@R36] Data were analysed in Stata V.13. The primary analysis used Student's t-tests to assess between-group differences in change over the 3-month trial in neuropsychological function and sleepiness. Age and premorbid intelligence were controlled for at baseline in the linear regression modelling of the effect of CPAP on change in neuropsychological function (see online [supplementary file](#SP1){ref-type="supplementary-material"}).[@R29] The effect of CPAP use on change in sleepiness in each week of the study was assessed using a mixed model linear regression, controlling for baseline sleepiness and with participant as a random effect.

Repeated measure analyses of variance assessed between-group differences in change in respiratory function over time. Between-group differences in medications (grouped as baclofen; benzodiazepines, opiates and other potentially sedative medications) were assessed with a logistic regression model controlling for baseline use.

Results {#s3}
=======

A total of 1810 consecutive incident cases of quadriplegia were screened for study inclusion between July 2009 and October 2015. Three hundred and thirty-two people met the inclusion criteria and underwent full, portable polysomnography. Of these, 59 (18%) had mild or no SDB (AHI ≤10), 273 (82%) had an AHI \>10 (OSA group) and 212 progressed to a three-night autotitrating CPAP trial. Respiratory events during the baseline sleep studies were predominantly hypopnoeas with progressively more obstructive, rather than central or mixed apnoeas, as the AHI increased ([table 1](#T1){ref-type="table"}). Eighty-one per cent of participants had a greater percentage of obstructive than central apnoeas. Four people (1.2%) had a greater percentage of their respiratory events that were classified as central apnoeas rather than hypopnoeas. Eight participants were excluded due to hypercapnia (see [figure 1](#F1){ref-type="fig"} and online [supplementary file](#SP1){ref-type="supplementary-material"} for participant details).

![Participant flow through the study. AHI, apnoea hypopnoea index; OSA, obstructive sleep apnoea.](thoraxjnl-2018-212319f01){#F1}

###### 

Respiratory event types and proportion from the baseline sleep studies (prerandomisation, n=332)

  OSA severity   Proportion of events (%)                
  -------------- -------------------------- ----- ------ ------
  AHI \<10       94.5                       2.6   2.5    0.05
  AHI 10--30     82.7                       3.7   13.3   0.3
  AHI \>30       52.2                       4.8   39.4   3.6
  All AHI        83.4                       3.2   11.8   1.5

AHI, apnoea hypopnoea index; OSA, obstructive sleep apnoea.

One hundred and sixty-four participants tolerated at least 4 hours of CPAP during run-in, four withdrew and 160 were randomised. One hundred and forty-nine completed the study ([figure 1](#F1){ref-type="fig"} and [table 2](#T2){ref-type="table"}). Participants were 90% male, slightly overweight (mean=25.2 kg/m^2^, SD=5.0) and had a restrictive ventilatory deficit (VC; 2.9 L, 0.95, % predicted 58.9%, 24.6; FEV~1~ 2.3 L/s, 0.78, % predicted 58.2%, 23.4). The average age was 47 (15) and the age distribution was bimodal (online [supplementary figure E1](#SP1){ref-type="supplementary-material"}) in line with changes in injury demographics.[@R1]

###### 

Participant characteristics at baseline

  --------------------------------------------------------------------------------------------------------
                                                         CPAP (n=73)\             Usual care (n=76)\
                                                         Mean (SD) or count (%)   Mean (SD) or count (%)
  ------------------------------------------------------ ------------------------ ------------------------
  Age, years                                             46.32 (15.59)            47.03 (14.87)

  Sex                                                                             

   Male                                                  67 (91.78)               67 (88.16)

  **Injury characteristics**                                                      

  AIS A                                                  29 (39.73)               26 (34.67)

  Lesion level                                                                    

   C2--C4                                                40 (54.79)               34 (44.72)

   C5--T1                                                33 (45.21)               42 (55.26)

  Time from injury to sleep study, days (median (IQR))   66 (49--90)              80 (60--123)

  Body mass index, kg/m^2^                               25.01 (4.77)             25.47 (5.15)

  Number likely to have preinjury OSA\*                  20/71 (28.6)             20/73 (27.4)

  Karolinska Sleepiness Scale                            4.86 (2.32)              4.24 (2.03)

  NAART                                                  31.01 (12.18)            33.53 (13.39)

  Vital capacity, L                                      2.83 (0.86)              2.91 (1.04)

  FEV~1~, L/s                                            2.24 (0.68)              2.27 (0.88)

  **Baseline sleep study indices**                                                

  Apnoea hypopnoea index (median (IQR))                  42.7 (22.7--69.3)        41.1 (24.4--55.2)

  Arousal index (median (IQR))                           23.9 (16.4--35.7)        25.1 (13.8--38.4)

  Sleep efficiency                                       67.12 (16.60)            66.41 (18.72)

  \% total sleep time with SpO~2~ \<90%                  10.30 (16.20)            9.49 (17.69)

  **Medications**                                                                 

  Baclofen                                               27 (37)                  34 (45)

  Benzodiazepines                                        24 (33)                  30 (40)

  Opiates                                                49 (67)                  55 (72)

  Other potentially sedating medications                 60 (82)                  64 (84)
  --------------------------------------------------------------------------------------------------------

Data are provided as count (n) or mean (SD) as appropriate.

\*Likelihood based on the Multivariate Apnoea Prediction Index.[@R57] Note that with medications, participants could be included across multiple categories.

AIS A,  American Spinal Injuries Association Impairment Scale A (motor and sensory complete lesion); C2--C4, second to fourth cervical cord lesion; C5--T1, fifth cervical to first thoracic cord lesion; NAART, North American Adult Reading Test; OSA, obstructive sleep apnoea.

Overall CPAP use averaged 2.9 (SD=2.3) hours per night with 15 (21%) of those randomised to autotitrating CPAP classified as fully 'adherent' (online [supplementary figure E2](#SP1){ref-type="supplementary-material"}). The average 95th centile CPAP was 9.29 (2.56) cmH~2~O. Final sleep studies on autotitrating CPAP demonstrated overall good control of OSA in those randomised to CPAP; oxygen desaturation index fell from 13.0 (1.8--44.5, median interquartile range) at baseline to 0.0 (0.0--0.7) at the repeat CPAP study (p\<0.01; table E2). Three participants had a residual oxygen desaturation index of greater than five events per hour. Six usual care participants were crossed over to autotitrating CPAP treatment by their clinical care teams. Of these, three were adherent on the *per protocol* analyses ([figure 2](#F2){ref-type="fig"}).

![Individual participant and average change in the primary outcome measure (PASAT). Individual participants represented by dots. Solid dots represent those participants classified as adherent overall and thus included in the *per protocol* analyses. Three of six participants randomised to control and provided CPAP by their clinical care teams were adherent with CPAP. Horizontal lines represent the average change in the primary outcome measure. PASAT, Paced Auditory Serial Addition Task.](thoraxjnl-2018-212319f02){#F2}

Study participants improved on the PASAT by an average of 17.0 (SD=28.1) over the 3 months; however, no significant difference was observed between groups in the intention-to-treat analysis (p=0.63, mean difference in improvement of 2.28, 95% CI −7.09 to 11.6; [table 3](#T3){ref-type="table"}). Results were similar after controlling for premorbid intelligence, age and OSA severity (group effect estimate of −1.15, 95% CI −10 to 7.7; table E2). In the *per protocol* analysis in the 18 adherent participants, the magnitude of effect was greater but not statistically significant (p=0.38, 6.30,   95% CI −7.75 to 20.34: table E3 and [figure 2](#F2){ref-type="fig"}). Performance on the PASAT was poor at baseline compared with both non-disabled control data (15%--33% worse) and other clinical populations (table E4).[@R38] All participants improved, although scores remained 7%--25% worse than controls.

###### 

Change scores and comparisons between participants randomised to usual care or CPAP

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                          Baseline mean (SD)   Final mean (SD)   Average within group change scores (95% CIs)   Between allocated group differences                                                                            
  ------------------------------------------------------- -------------------- ----------------- ---------------------------------------------- ------------------------------------- ----------------------- ------------------------ ----------------------- ------
  PASAT[\*](#tblfn6){ref-type="fn"}                       99.17\               99.69\            117.66\                                        116.92\                               **18.19**\              **15.91**\               2.29\                   0.63
                                                          (45.26)              (46.28)           (45.71)                                        (47.17)                               **(12.67 to 23.71)**    **(8.40 to 23.41)**      (−7.09 to 11.66)        

  KSS†                                                    4.86\                4.24\             3.51\                                          4.14\                                 **−1.36**\              −0.09\                   **−1.26**\              0.01
                                                          (2.32)               (2.03)            (1.82)                                         (2.02)                                **(−1.99 to  −0.72)**   (−0.79 to 0.61)          **(−2.20, to −0.32)**   

  RAVLT immediate recall[\*](#tblfn6){ref-type="fn"}      6.45\                6.12\             7.49\                                          7.03\                                 **1.04**\               **0.91**\                0.13\                   0.70
                                                          (2.27)               (1.93)            (2.22)                                         (2.50)                                **(0.49 to 1.59)**      **(0.49 to 1.33)**       (−0.55 to 0.81)         

  RAVLT total recall[\*](#tblfn6){ref-type="fn"}          47.62\               46.95\            50.53\                                         49.93\                                **2.92**\               **2.99**\                −0.07\                  0.96
                                                          (12.27)              (11.30)           (11.56)                                        (12.51)                               **(0.68 to 5.16)**      **(0.97 to 5.00)**       (−3.05 to 2.91)         

  RAVLT learning[\*](#tblfn6){ref-type="fn"}              5.00\                5.41\             4.15\                                          4.53\                                 **−0.85**\              **− 0.88**\              0.03\                   0.94
                                                          (1.89)               (2.05)            (2.34)                                         (2.31)                                **(−1.53 to −0.17)**    **(−1.50 to −0.26)**     (−0.88 to 0.94)         

  RAVLT short term memory[\*](#tblfn6){ref-type="fn"}     9.51\                9.45\             9.99\                                          10.38\                                0.51\                   0.99\                    −0.47\                  0.34
                                                          (3.35)               (3.83)            (3.13)                                         (3.55)                                (−0.22 to 1.25)         (0.32 to 1.65)           (−1.45 to 0.51)         

  RAVLT delayed recall[\*](#tblfn6){ref-type="fn"}        8.77\                8.97\             9.68\                                          10.09\                                **0.94**\               **1.08**\                −0.14\                  0.77
                                                          (3.87)               (4.00)            (3.70)                                         (3.58)                                **(0.27 to 1.62)**      **(0.40 to 1.76)**       (−1.09 to 0.81)         

  RAVLT forgetting†                                       2.69\                2.53\             1.96\                                          1.47\                                 **−0.75**\              **−1.05**\               0.30\                   0.49
                                                          (2.45)               (2.43)            (2.14)                                         (2.20)                                **(−1.40 to  −0.10)**   **(−1.64 to --0.47)**    (−0.56 to 1.17)         

  RAVLT recognition[\*](#tblfn6){ref-type="fn"}           12.70\               13.51\            13.55\                                         13.63\                                **0.73**\               0.12\                    0.61\                   0.07
                                                          (2.43)               (1.51)            (1.64)                                         (1.63)                                **(0.20 to 1.27)**      (−0.30 to 0.54)          (−0.06 to 1.29)         

  SDMT[\*](#tblfn6){ref-type="fn"}                        42.21\               42.19\            46.14\                                         43.62\                                **3.73**\               1.43\                    2.30\                   0.16
                                                          (11.04)              (14.10)           (11.74)                                        (15.10)                               **(1.52 to 5.93)**      (−0.94 to 3.81)          (−0.93 to 5.52)         

  Digit Span forwards[\*](#tblfn6){ref-type="fn"}         9.78\                9.32\             10.14\                                         9.53\                                 0.36\                   0.21\                    0.15\                   0.67
                                                          (2.17)               (2.35)            (2.27)                                         (2.43)                                (−0.16 to 0.87)         (−0.23 to 0.65)          (−0.52 to 0.81)         

  Digit Span backwards[\*](#tblfn6){ref-type="fn"}        8.05\                7.91\             8.55\                                          8.13\                                 **0.49**\               0.22\                    0.27\                   0.43
                                                          (2.05)               (2.18)            (2.68)                                         (2.58)                                **(0.02 to 0.97)**      (−0.27 to 0.71)          (−0.41 to 0.95)         

  HADS anxiety†                                           5.57\                5.25\             4.42\                                          4.95\                                 **−1.10**\              −0.30\                   −0.79\                  0.17
                                                          (3.96)               (3.84)            (3.42)                                         (3.25)                                **(−1.92 to  −0.28)**   (−1.11 to 0.50)          (−1.93 to 0.34)         

  HADS depression†                                        6.28\                5.72\             5.16\                                          5.22\                                 **−1.06**\              −0.65\                   −0.40\                  0.50
                                                          (3.78)               (4.07)            (3.42)                                         (3.80)                                **(−1.75 to −0.36)**    (−1.61 to 0.31)          (−1.58 to 0.78)         

  POMS tension/anxiety†                                   9.21\                8.22\             8.16\                                          6.45\                                 −1.04\                  **−1.81**\               0.77\                   0.38
                                                          (7.00)               (6.01)            (6.42)                                         (5.49)                                (−2.38 to 0.30)         **(−2.95 to --0.67)**    (−0.97 to 2.51)         

  POMS depression†                                        11.90\               11.68\            9.84\                                          8.81\                                 −2.07\                  **−2.96**\               0.89\                   0.57
                                                          (10.40)              (10.94)           (10.53)                                        (10.11)                               (−4.27 to 0.13)         **(−5.19 to --0.73)**    (−2.21 to 4.00)         

  POMS anger†                                             7.59\                7.15\             8.53\                                          6.61\                                 0.95\                   −0.61\                   1.55\                   0.11
                                                          (6.28)               (6.14)            (7.31)                                         (5.50)                                (−0.48 to 2.37)         (−1.91 to 0.69)          (−0.36 to 3.47)         

  POMS vigour[\*](#tblfn6){ref-type="fn"}                 16.11\               16.76\            16.96\                                         17.77\                                0.85\                   1.14\                    −0.29\                  0.79
                                                          (6.46)               (6.17)            (6.64)                                         (5.60)                                (−0.70 to 2.40)         (−0.34 to 2.61)          (−2.41 to 1.84)         

  POMS fatigue†                                           10.75\               10.57\            9.66\                                          9.00\                                 −1.10\                  **−1.64**\               0.54\                   0.57
                                                          (6.30)               (6.03)            (5.93)                                         (5.82)                                (−2.37 to 0.17)         **(−3.01 to --0.26)**    (−1.32 to 2.40)         

  POMS confusion†                                         9.08\                7.62\             7.92\                                          7.27\                                 −1.16\                  −0.42\                   −0.75\                  0.34
                                                          (5.30)               (4.26)            (5.20)                                         (3.99)                                (−2.45 to 0.13)         (−1.29 to 0.45)          (−2.29 to 0.80)         

  POMS total†                                             32.42\               28.47\            27.15\                                         20.37\                                −5.27\                  **−8.57**\               3.29\                   0.49
                                                          (32.81)              (31.38)           (35.67)                                        (29.17)                               (−12.22 to 1.67)        **(−14.93 to --2.21)**   (−6.04 to 12.63)        

  AQoL illness[\*](#tblfn6){ref-type="fn"}                0.15\                0.16\             0.36\                                          0.35\                                 **0.20**\               **0.18**\                0.02\                   0.65
                                                          (0.20)               (0.21)            (0.30)                                         (0.29)                                **(0.13 to 0.27)**      **(0.13 to 0.24)**       (−0.07 to 0.11)         

  AQoL relationships[\*](#tblfn6){ref-type="fn"}          0.70\                0.71\             0.76\                                          0.76\                                 0.06\                   0.04\                    0.01\                   0.74
                                                          (0.26)               (0.25)            (0.17)                                         (0.18)                                (−0.003 to 0.12)        (−0.02 to 0.11)          (−0.07 to 0.10)         

  AQoL sensory[\*](#tblfn6){ref-type="fn"}                0.95\                0.94\             0.95\                                          0.93\                                 −0.01\                  −0.001\                  −0.01\                  0.51
                                                          (0.07)               (0.10)            (0.08)                                         (0.09)                                (−0.03 to 0.01)         (−0.02 to 0.01)          (−0.03 to 0.02)         

  AQoL mental health[\*](#tblfn6){ref-type="fn"}          0.81\                0.81\             0.83\                                          0.84\                                 0.02\                   0.03\                    −0.01\                  0.83
                                                          (0.16)               (0.17)            (0.14)                                         (0.12)                                (−0.02 to 0.07)         (−0.01 to 0.07)          (−0.06 to 0.05)         

  AQoL total health utility[\*](#tblfn6){ref-type="fn"}   0.14\                0.15\             0.29\                                          0.27\                                 **0.15**\               **0.11**\                0.03\                   0.32
                                                          (0.14)               (0.16)            (0.23)                                         (0.19)                                **(0.09 to 0.20)**      **(0.08 to 0.15)**       (−0.03 to 0.10)         

  BNSQ†                                                   42.31\               42.07\            36.71\                                         38.82\                                **−6.44**\              **−3.58**\               2.86\                   0.16
                                                          (11.18)              (11.28)           (10.66)                                        (11.58)                               **(−9.27 to 3.62)**     **(−6.42 to --0.74)**    (−1.11 to 6.84)         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bold indicates significant within-group improvement from baseline. P values refer to between-group comparisons of change scores.

\*Higher test scores represent better functioning.

†Lower test scores represent better functioning.

AQoL, Assessment of Quality of Life; BNSQ, Basic Nordic Sleep Questionnaire; Digit Span, Digit Span subtest of the Wechsler Adult Intelligence Scale IV; HADS, Hospital Anxiety and Depression Scale; KSS, Karolinska Sleepiness Scale; PASAT, Paced Auditory Serial Addition Task; KSS, Karolinska Sleepiness Scale; POMS, Profile of Mood States; RAVLT, Rey Auditory Verbal Learning Test; SDMT, Symbol Digit Modalities Test.

Sleepiness measured by the KSS was significantly improved (lower scores are less sleepy) by autotitrating CPAP on intention-to-treat analysis ([table 3](#T3){ref-type="table"}; p\<0.01, mean difference in improvement of −1.26, 95% CI −2.2 to --0.32), after controlling for baseline predictors (−0.65, 95% CI −1.3 to --0.01; table E2) and in each week in which participants were classified as adherent (online [supplementary figure E2](#SP1){ref-type="supplementary-material"}; p=0.004, −0.45, 95% CI −0.77 to --0.14). The mean improvement was marginally larger on *per protocol* (table E3), but the difference was no longer statistically significant (p=0.07; −1.34, 95% CI −2.80 to 0.12). The BNSQ measure of sleepiness was non-significantly improved by CPAP on intention to treat (p=0.16; −2.86, 95% CI −0.11 to 6.84) but significantly improved after controlling for baseline predictors (−3.42, 95% CI −6.67 to --0.16; table E2) and on *per protocol* (p=0.003; −9.09, 95% CI −3.2 to --15; table E3). The POMS Fatigue score improved overall (−1.37, 95% CI −2.2 to --0.44) but was not different between groups (p=0.57, [table 3](#T3){ref-type="table"}).

Ten of the 27 outcome measures ([table 3](#T3){ref-type="table"}) significantly improved within group over time. The intention-to-treat, linear regression models and the *per protocol* comparisons, found no between-group differences in any of the outcome measures other than sleepiness (KSS). Linear regression modelling of change in neuropsychological function after controlling for the baseline values of age, premorbid intelligence and AHI found that being younger was associated with significantly increased overall improvement in the PASAT, the Symbol Digit Modality Test and RAVLT 'delayed recall' and 'forgetting' domains (table E2). A higher premorbid intelligence score (NAART) was also associated with increased overall improvement in the PASAT, sleepiness on the BNSQ, the Symbol Digit Modality Test and on RAVLT 'immediate recall' and 'total recall' (table E2).

The use of pain and antispasmodic medications that were potentially sedating was high at both baseline and at study conclusion ([tables 1 and 4](#T1 T4){ref-type="table"}). Baclofen prescription increased at study conclusion but proportionally less in the CPAP group (52% vs 75%, p=0.03).

###### 

Baseline and end-study (3 months) usage of potentially sedating medications

  Medications                              CPAP, n (%)   Usual care, n (%)   P values             
  ---------------------------------------- ------------- ------------------- ---------- --------- ------
  Baclofen                                 27 (37)       38 (52)             34 (45)    54 (71)   0.03
  Benzodiazepines                          24 (33)       22 (30)             30 (40)    21 (28)   0.43
  Opiates                                  49 (67)       43 (60)             55 (72)    48 (63)   0.74
  Other potentially sedating medications   60 (82)       64 (88)             64 (84)    68 (89)   0.76

P values represent effect of group allocation in the presence or absence of these medications at the final assessment. Differences were assessed with a logistic regression model that controlled for individuals' baseline use and group allocation.

No differences were observed between randomisation groups in the frequency of autonomic dysreflexia events per week (p=0.37; −0.17, 95% CI −0.55 to --0.21), serious adverse events or measures of heart rate variability (see [supplementary data)](#SP1){ref-type="supplementary-material"}.

Discussion {#s4}
==========

This study confirmed that SDB is highly prevalent (82% of those tested with full polysomnography  (PSG)) and that neurocognitive performance is substantially impaired after an acute cervical spinal cord injury. Treatment with autotitrating CPAP did not improve PASAT scores more than the improvement seen over time on both intention-to-treat and *per protocol* analyses. As previously reported, neurocognitive impairment was associated with the severity of SDB at baseline.[@R29] The autotitrating CPAP effectively treated SDB when people were able to tolerate the therapy and the SDB persisted in those untreated with autotitrating CPAP. Subjective sleepiness was significantly improved by autotitrating CPAP on the intention-to-treat analyses despite the low overall adherence.

The Apnea Positive Pressure Long-term Efficacy Study  (APPLES) study, a large randomised controlled trial of CPAP versus sham-CPAP in 1098 able-bodied participants,[@R39] found a small improvement in a subset of a battery of neurocognitive tests after 2 months of active therapy. The APPLES authors speculated that the relatively high measured intelligence of their sample, and an associated cognitive reserve that was potentially resistant to the detrimental effects of SDB,[@R40] may have masked any opportunity for improved neurocognitive function with CPAP. The NAART-estimated average intelligence in our study was 23% lower than general population data (33.8/61 and 41.4/61, respectively; online [supplementary etable 5](#SP1){ref-type="supplementary-material"})[@R41] and thus our sample exhibited less cognitive reserve and should have provided more opportunity for improvement as suggested by the APPLES authors. Furthermore, the SDB treated in the current study was acutely caused by the cervical injury[@R5] and as such potentially spared the less reversible, structural neural and neuropsychological changes seen in the able bodied with long-standing SDB.[@R40] Despite controlling for cognitive reserve, age and SDB severity as suggested in a recent review,[@R40] the current study suggests that treating SDB does not improve neurocognitive dysfunction overall, and specifically attention and information processing as measured by the PASAT, in acute quadriplegia.

A number of controlled trials of CPAP for SDB have demonstrated improvements in sleepiness with treatment.[@R39] The minimally clinical important difference in the KSS has not been defined; however, the 1.26 unit relative reduction in sleepiness with CPAP observed on the intention-to-treat analysis compares favourably with the reported difference of 1.35 between people with and without moderate SDB[@R44] and the approximate 1.5 unit increase in KSS observed after a night of CPAP withdrawal in people successfully treated for SDB.[@R45] Improved sleepiness was also observed on both the KSS and the BNSQ total scores after controlling for baseline confounders. Additionally, the analyses of weekly KSS reports compared with CPAP use or not in the preceding week suggest that effective treatment directly reduced sleepiness, although as these sleepiness weekly data were self-reported and thus not blinded to group, a placebo response cannot be excluded. The sleepiness changes over multiple measures suggest that the improvement with autotitrating CPAP was both statistically and clinically significant.

Potentially sedating and ventilatory control modifying medications are used commonly in SCI care and could confound measures of neuropsychological function and sleepiness. There was no change in the proportions of benzodiazepine, opiate or other potentially sedating medications over time except for baclofen. Baclofen, a gamma aminobutyric acid-B agonist, is a centrally acting, antispasmodic agent and muscle relaxant used to treat spasticity in quadriplegia that has been shown to have a sedative effect but not to worsen OSA in a non-disabled sample.[@R46] The majority of studies in SCI have similarly found no effect of baclofen on the AHI.[@R13] Baclofen use increased by approximately 40% in the CPAP group and 60% in the usual care arm (online [supplementary etable 6](#SP1){ref-type="supplementary-material"}). In people with quadriplegia, periodic leg movements are common,[@R6] worsened by SDB[@R47] and have been treated with baclofen as 'spasticity and spasm'.[@R48] The smaller increase in baclofen in the CPAP group could partially explain the between-group difference in sleepiness, or alternatively, less spasm associated with OSA treatment may have reduced baclofen prescription by clinicians.

The current study confirmed substantial neurocognitive impairment (online [supplementary etable 5](#SP1){ref-type="supplementary-material"}) in a sample where significant acute brain injury was excluded[@R29] and demonstrated clinically important improvement in PASAT scores in both trial arms. Approximately one-third of test battery scores improved significantly within group ([table 2](#T2){ref-type="table"}), and thus while resolution of comorbid mild traumatic brain injury[@R49] and/or a learning effect cannot be excluded, there was no statistically significant group mean difference on any domain other than sleepiness. Recent research has revealed that isolated SCI is associated with generalised cortical neuroinflammation,[@R50] and we speculate that resolution of inflammation may partially explain the overall improvement in attention and information processing. Further research exploring this hypothesis and its effect on rehabilitation may be warranted.

In common with most pragmatic randomised clinical controlled trials, this study had a number of limitations. In particular, the average use of autotitrating CPAP was low at 2.9 hours per night. The reasons for this poor adherence in people with quadriplegia are multifactorial (as in the non-disabled), but the most commonly reported complaints in quadriplegia are nasal congestion, an inability to fall asleep with the mask on and no perceived benefit or noticeable change in symptoms.[@R27] CPAP remains the first-line therapy for SDB, although there is increasing recognition that alternate therapies are needed. Emerging evidence suggests that SDB in quadriplegia may result from different combinations of phenotypic factors than in the non-disabled population[@R22] and that some of these factors, in particular a markedly raised nasal resistance,[@R20] may require alternative treatment targets.

Autotitrating CPAP usage, while low, was sufficient to improve sleepiness. Similar CPAP usage has been demonstrated in populations such as aged care (median use of 1:52 hours per night at 3 months)[@R43] where a comparable improvement in sleepiness without any differential improvement in cognitive function was observed. The usage observed in the current study is also similar to the recent Sleep Apnoea Cardiovascular Endpoints (SAVE) trial of 2717 people where CPAP for OSA was used on average for 3.3 hours per night and a 10.4% improvement in sleepiness was observed.[@R42] The aforementioned APPLES study reported average adherence of 4.2 hours in the active arm,[@R39] with similar sleepiness changes, particularly in those with more severe baseline OSA. Despite the low adherence overall, *per protocol* analyses examining 'good users' did not suggest any improvement in attention and information processing favouring treatment. In contrast, the sleepiness improvement with CPAP was significant in both the primary comparisons and in the analysis relating sleepiness to usage in the prior week. The *per protocol* analysis of sleepiness demonstrated a larger effect size favouring autotitrating CPAP. We speculate this failed to achieve statistical significance (online [supplementary etable 4](#SP1){ref-type="supplementary-material"}; p=0.07), due to the low numbers who attained our conservative measure of adherence.

While the majority of respiratory events in the current study were hypopnoeas or obstructive apnoeas[@R32] and daytime hypercapnia was rare, bilevel positive airway pressure (PAP) rather than autotitrating CPAP may be hypothesised to have been a 'better tolerated' or 'more effective' therapy. Sleep-onset hypoventilation[@R15] and central sleep apnoea[@R15] have been described in a series of smaller, laboratory-based studies; however, larger and, particularly population-based, samples, have consistently reported predominant OSA in quadriplegia.[@R6] Occasional central sleep apnoea is observed in larger trials, but as in the current inception cohort, it appears to be the exception not the rule. There is no published direct comparison of adherence with bilevel PAP versus CPAP therapy in quadriplegia and as such it is not possible to answer whether CPAP or bilevel PAP is 'best' in quadriplegia. A recent case series in spinal cord injury (74% quadriplegia) described bilevel PAP to treat OSA and bilevel PAP with volume-assured pressure support to treat OSA and sleep (but not necessarily daytime) hypoventilation.[@R56] If those lost to follow-up in that paper are assumed to be non-adherent, then overall PAP use of 28% at 3 months is similar to the 21% observed in our experiment. As such, we believe it is difficult to assert that bilevel PAP would have materially affected adherence and outcomes, although this is speculation that warrants further investigation.

As recently reviewed,[@R40] the relationship between SDB including OSA, neurocognitive impairments and CPAP is complex. Groups of people with OSA are neurocognitively impaired compared with non-OSA controls but not all those with OSA demonstrate neurocognitive dysfunction. Comorbid conditions, ageing, cognitive reserve and other factors confound the effect of SDB on neurocognition, and there is no clear 'dose' of CPAP that is consistently associated with improvement. It remains possible that the average CPAP use in the current study was insufficient to reverse the SDB associated, neurocognitive impairments observed at baseline.[@R29] APPLES demonstrated small improvements in executive function but only in those most sleepy at baseline,[@R39] whereas the previously mentioned aged-care trial with comparable CPAP use to the current study found no effect on cognitive function.[@R43] The Bucks *et al* review concluded that it remains unclear whether CPAP can reverse neurocognitive dysfunction. The current study findings in a sensitised quadriplegia model with both less cognitive reserve and acute SDB supports this uncertainty.

This study found that treatment of OSA with CPAP in acute quadriplegia did not modify neuropsychological improvement as measured with the PASAT but was associated with improved sleepiness. In a non-disabled population, improving sleepiness is seen as a worthwhile goal of treatment, and worse sleepiness is linearly associated with poorer health status in quadriplegia.[@R16] As such, we suggest that treating sleepiness from SDB is important in quadriplegia and that exploration of novel therapies for those who are intolerant of CPAP deserves further investigation.
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